Showing 1 - 10 of 6,846
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …
Persistent link: https://www.econbiz.de/10013211641
Generic pharmaceuticals provide low-cost access to treatment. Despite their chemical equivalence to branded products …
Persistent link: https://www.econbiz.de/10012949948
Pharmaceutical firms' use of secondary patents to extend periods of exclusivity generates concerns among policymakers worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these measures have received considerable attention, there is...
Persistent link: https://www.econbiz.de/10012964387
The extent of pharmaceutical advertising and promotion can be characterized by a balancing act between profitable demand expansions and potentially unfavorable subsequent regulatory actions. However, this balance also depends on the nature of competition (e.g. monopoly versus oligopoly). In this...
Persistent link: https://www.econbiz.de/10013123314
Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation. Public prescription drug insurance escapes that trade-off and achieves an elusive goal: lowering static deadweight loss, while simultaneously encouraging dynamic investments in...
Persistent link: https://www.econbiz.de/10012775801
There is a long-standing literature that recognizes that an efficient solution in correcting a consumption externality is through applying subsidies and taxes that line up private incentives with social ones. An equally long-standing literature tackles the appropriate methods of generating the...
Persistent link: https://www.econbiz.de/10013237532
how consumers respond to drug withdrawals. In theory, remaining drugs in the therapeutic class could enjoy competitive …
Persistent link: https://www.econbiz.de/10012752599
During the 1980s the share of prescriptions sold by retail pharmacies that was accounted for by generic products roughly doubled. The price response to generic entry of brand-name products has been a source of controversy. In this paper we estimate models of price responses to generic entry in...
Persistent link: https://www.econbiz.de/10014158702
We study choice over prescription insurance plans by the elderly using government administrative data to evaluate how these choices are made and evolve over time. We find that there is large "foregone savings" from not choosing the lowest cost plan that has grown over time. We develop a...
Persistent link: https://www.econbiz.de/10013079765
We study the effects of an institution that pools patents across geographical markets on the licensing and adoption of life-saving drugs in low- and middle-income countries. Using data on licensing and sales for HIV, hepatitis C and tuberculosis drugs, we show that there is an immediate and...
Persistent link: https://www.econbiz.de/10014264413